Metastatic Hepatocellular Carcinoma Treatment Receives Breakthrough Therapy Designation
The FDA has granted a breakthrough therapy for atezolizumab Tin combination with bevacizumab for the treatment of advanced or metastatic hepatocellular carcinoma.
Unique Mutation Found in Amyloid Diseases Sheds Light on Potential Treatment
Researchers have identified a unique mutation in a deceased
transthyretin (TTR) amyloidosis patient, which sheds light on the disease and may help identify new targets for treatment.
New Drugs Needed to Target Pediatric Cancers
E. Anders Kolb, MD, emphasizes the difference between pediatric and adult cancers and the need to develop new treatments developed specifically for children.
Mutations in TRAF7 Gene Associated with Mysterious Multisystem Disorder
Researchers at Baylor College of Medicine find that mutations in the gene
are associated with a multisystem disorder presented by 7 patients.
Uncovering Rare Genetic Factors with Multiplex Germline Testing
Pauline Funchain, MD,
discusses the use of multiplex germline testing for rare diseases and cancers and explains the benefits of uncovering genetic factors.
CALR-Mutant Myeloproliferative Neoplasms Induced by MPL Downstream Activation
Study performed by researchers at Juntendo University reveals molecular mechanisms that trigger CALR-mutant
myeloproliferative neoplasms (MPNs).
sNDA Submitted to FDA for Venetoclax in AML Patients Ineligible for Intensive Chemotherapy
AbbVie has submitted a supplemental new drug application to the FDA for venetoclax to be used in combination with HMA or LDAC for the treatment of AML patients who are ineligible for intensive chemotherapy.
Ibrutinib Combination Therapy for DLBCL Falls Short of Phase 3 Primary Endpoint
Results from a phase 3 clinical trial evaluating an ibrutnib combination with a chemotherapy regimen for the treatment of diffuse large B-cell lymphoma fails to meet primary endpoint.
FDA Grants sBLA to Advanced Hepatocellular Carcinoma
The FDA has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for pembrolizumab (KEYTRUDA) for the treatment of advanced hepatocellular carcinoma (HCC).
The Pivotal Role of Clinical Trials in Lymphoma Treatments
Owen A. O’Connor, MD, PhD, outlines the importance of clinical trials and reviewed strides made in lymphoma treatments.
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.